KAKhalil Ansarin

Khalil Ansarin

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Khalil Ansarin has a total of 377 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Gene Expression Analysis of miR-142-3p/BMAL1/PPARA and miR-24-3p/PER2/PPARG Pathways: Insights into the Link between Short Sleep Duration and Obesity in Humans

    by A. Ansarin, D. Shanehbandi, A. Ostadrahimi, H. Zarredar, N. Gilani, K. Ansarin

    Short sleep duration (SSD) is a recognized risk factor for obesity, yet the underlying molecular mechanisms remain poorly understood. This study investigates the expression of key microRNAs (miR-142-3p and miR-24-3p), their respective regulatory targets (BMAL1 and PER2), and the downstream targets of these genes (PPARA and PPARG), to elucidate potential pathways linking SSD and obesity. Gene expression levels were analyzed by qRT-PCR and in four groups of participants: normal sleepers with normal weight (Group A), normal sleepers with obesity (Group B), short sleepers with normal weight (Group C), and short sleepers with obesity (Group D). Results revealed significant upregulation of miR-142-3p (p < 0.05) and corresponding downregulation of BMAL1 (p < 0.05) across all experimental groups compared to controls. PPARA, a downstream target of BMAL1, was significantly downregulated only in obese groups (A vs. B, p = 0.019, and C vs. D, p = 0.004). Similarly, miR-24-3p expression was significantly elevated in SSD and obesity groups (p < 0.05), leading to suppression of PER2 (p < 0.05). Notably, PPARG expression was upregulated in SSD groups (p < 0.05) and obese participants only in the context of SSD (C vs. D, p = 0.039). These results highlight a distinct role for the miR-24-3p/PER2/PPARG pathway and also limited involvement of the miR-142-3p/BMAL1/PPARA axis in SSD-associated obesity. Future research should explore the downstream pathways of BMAL1 and interventional strategies to restore circadian and metabolic homeostasis.

  • Evaluating the endothelial and metabolic effects of CPAP therapy in obstructive sleep apnea patients: Insights from a comprehensive meta-analysis

    by Sara Daneshvar, Ensiyeh Seyedrezazadeh, Maryam Seyyedi, Sevda Jafari, Atefeh Ansarin, Neda Gilani, Babak Mokhlesi, Khalil Ansarin


  • Tracing the evolution in sleep apnea detection: a review from traditional non-contact under-the-mattress devices to advanced AI-driven methods

    by Sara Daneshvar, Mehran Rahimi, Khalil Ansarin

    Background Sleep apnea is traditionally diagnosed with polysomnography (PSG), which, while effective, is costly, time-consuming, and obtrusive. Recent advancements in biosensing technologies have facilitated the development of under-the-mattress devices as potential alternatives for detecting sleep apnea. Methods We reviewed the literature across PubMed, Embase, Web of Science, and Scopus, focusing on studies that assessed mattress-like or under-the-mattress biosensing devices for sleep apnea. 15 studies were included as illustrative examples of recent progress. Results Our review assessed studies on innovative sensor technologies for sleep apnea detection. These studies demonstrated the efficacy of various sensors—such as Load Cells, Emfit, and PVDF—along with advanced radar and machine learning methods, in accurately identifying sleep apnea events. Results indicated that most studies reported good overall performance of mattress-based systems compared to traditional polysomnography, though variability across devices was observed. Conclusion Under-the-mattress biosensing devices appear to be promising as cost-effective, user-friendly, and unobtrusive alternatives to PSG for sleep apnea detection. Their high-performance metrics suggest that these devices are viable options for both clinical settings and home use.

  • Open Access

    The synergistic impact of sleep duration and obesity on metabolic syndrome risk: exploring the role of microRNAs

    by Atefeh Ansarin, Dariush Shanehbandi, Habib Zarredar, Alireza Ostadrahimi, Neda Gilani, Khalil Ansarin

    Introduction: Given the well-established association between metabolic syndrome (MetS) and obesity, this study elucidates the influences of sleep duration and weight on MetS risk and explores the potential role of miRNAs as underlying mechanisms. Methods: According to sleep logs and biochemistry tests, this study investigated the association between MetS and its components, sleep duration, and weight in four subgroups: A: normal sleepers with normal weight (N = 145), B: normal sleepers with obesity (N = 140), C: short sleepers with normal weight (N = 130), and D: short sleepers with obesity (N = 142). Chi-square, one-way ANOVA, and Tukey’s post hoc tests were used for statistical analysis. Furthermore, following total RNA isolation by TRIzol from blood samples, cDNA was synthesized using stem-loop technique. Quantitative real-time polymerase chain reaction (qRT-PCR) was then employed to evaluate the expression levels of miR-33a, miR-378a, miR-132-3p, and miR-181d. The data were analyzed using one-way ANOVA. Results: Our findings revealed the strongest association between MetS prevalence and individuals in group D (short sleepers with obesity; Cramer's V = 0.649, P < 0.001). This observation underscores the synergistic effect of short sleep and obesity on MetS risk. Furthermore, there was an independent association between short sleep duration and elevated triglyceride levels (P < 0.05). MicroRNA expression analysis revealed downregulation of miR-33a and miR-181d in B, C, and D groups compared to the normal group. Conversely, miR-132-3p expression was upregulated in the B, C, and D groups. Conclusion: Short sleep and obesity synergistically elevate MetS risk, potentially via miR-33a and miR-181d downregulation and miR-132-3p upregulation, impacting triglyceride metabolism.


  • Open Access

    Unraveling the link between PTBP1 and severe asthma through machine learning and association rule mining method

    by Saeed Pirmoradi, Seyed Mahdi Hosseiniyan Khatibi, Sepideh Zununi Vahed, Hamed Homaei Rad, Amir Mahdi Khamaneh, Zahra Akbarpour, Ensiyeh Seyedrezazadeh, Mohammad Teshnehlab, Kenneth R. Chapman, Khalil Ansarin

    Severe asthma is a chronic inflammatory airway disease with great therapeutic challenges. Understanding the genetic and molecular mechanisms of severe asthma may help identify therapeutic strategies for this complex condition. RNA expression data were analyzed using a combination of artificial intelligence methods to identify novel genes related to severe asthma. Through the ANOVA feature selection approach, 100 candidate genes were selected among 54,715 mRNAs in blood samples of patients with severe asthmatic and healthy groups. A deep learning model was used to validate the significance of the candidate genes. The accuracy, F1-score, AUC-ROC, and precision of the 100 genes were 83%, 0.86, 0.89, and 0.9, respectively. To discover hidden associations among selected genes, association rule mining was applied. The top 20 genes including the PTBP1, RAB11FIP3, APH1A, and MYD88 were recognized as the most frequent items among severe asthma association rules. The PTBP1 was found to be the most frequent gene associated with severe asthma among those 20 genes. PTBP1 was the gene most frequently associated with severe asthma among candidate genes. Identification of master genes involved in the initiation and development of asthma can offer novel targets for its diagnosis, prognosis, and targeted-signaling therapy.


  • Male-biased association of endothelial nitric oxide synthase Asp298Glu substitution (NOS3-c.894G/T) with asthma risk and severity

    by Younes Aftabi, Amir Amiri-Sadeghan, Neda Gilani, Tahereh Zahedi, Mohamad Taghi Khodayari, Elnaz Faramarzi, Ensiyeh Seyedrezazadeh, Khalil Ansarin

    Objective: The nitric-oxide pathway plays a crucial role in the pathogeneses of asthma and NOS3-encoded endothelial nitric oxide synthase is one of the main components of the pathway. Variants of NOS3 are known to contribute to asthma development and pathophysiology. Methods: We investigated the association of NOS3-c.894G/T (rs1799983) with asthma risk and severity by studying frequencies of its genotypes and alleles in 555 asthmatics (93 intermittent, 240 mild, 158 moderate, and 64 severe asthma cases) and 351 control participants using the PCR-FRLP method, logistic regression analysis and generalized ordered logit estimates. Results: GT genotype (ORadj:1.39; CI:1.04-1.85; P = 0.026), dominant model GT + TT (ORadj:1.41; CI:1.07-1.87; P = 0.015), and T allele (ORadj:1.32; CI:1.05-1.67; P = 0.018) was associated with increased ORs in asthmatics. Also, the frequency of GT + TT (ORadj:1.55; CI:1.01-2.38; P = 0.044) was significantly higher in males. Furthermore, GT genotype (ORadj:1.39; CI:1.04-1.85; P = 0.024), GT + TT (ORadj:1.42; CI:1.07-1.87; P = 0.014), and T allele (ORadj:1.32; CI:1.05-1.66; P = 0.018) in total population and GT + TT (ORadj:1.56; CI:1.02-2.37; P = 0.04) in males were significantly associated with increased risk of severe, moderate, mild, intermittent asthma vs. controls. Also, GT genotype (ORadj:1.39; CI:1.02-1.91; P = 0.039) was significantly more frequent in severe, moderate grades vs. lower severity grades in the total population. Frequencies of GT genotype (ORadj:1.77; CI:1.05-3.00; P = 0.032) and GT + TT (ORadj:1.74; CI:1.04-2.90; P = 0.036) in total population and GT genotype (ORadj:2.40; CI:1.16-4.97; P = 0.018) and GT + TT (ORadj:2.30; CI:1.12-4.74; P = 0.023) in male subpopulation were significantly higher in severe cases compared to lower grades. Conclusions: NOS3-c.894G/T may be associated with asthma risk and its severer grades, with greater effects in men.


  • Open Access

    Injection of intravenous immunoglobulin (IVIg) for the treatment of Coronavirus induced cytokine storm

    by Farahnoosh Farnood, Hamed Valizadeh, Khalil Ansarin, Sepideh Zununi Vahed, Armin Sadeghi, Leila Namvar, Farid Rashidi, Seyyedeh Mina Hejazian, Mohammadreza Ardalan, Akbar Sharifi

    Background. COVID-19 disease is the cause of daily morbidity and mortality worldwide due to its high transmissibility and pathogenicity. To date, intravenous immunoglobulin (IVIg) injection has been used as one of the various treatments for this disease. This study aimed to determine the effect of IVIg injection on the treatment of patients with Coronavirus-induced cytokine storm. Methods. A total of 174 patients with COVID-19 were included in this study based on their clinical characteristics and laboratory findings and were divided into two groups of IVIg recipients and non-recipients according to the treatment they received. Statistical analysis was performed using SPSS version 22.0. A p-value less than 0.05 was considered statistically significant. Results. IVIg was used to treat merely 20 patients and Kaletra and hemoperfusion drugs were used more among IVIg recipient patients (P=0.003 and P=0.001, respectively). COVID-19-positive PCR tests were significantly more frequent among IVIg recipients (P=0.026). The polymorphonuclear neutrophil (PMN) count (P=0.007) and sodium level (P=0.007) were significantly higher in the IVIg recipient group on the first admission day. Moreover, INR levels in the IVIg recipient group were significantly lower on the seventh admission day (P=0.020). The median of total intensive care unit (ICU) duration of hospitalization among IVIg recipients was significantly higher (P=0.001). Conclusion. It seems that the use of IVIg in COVID-19 patients should be further investigated. Practical Implications. IVIg injection could decrease mortality and slightly increase the survival rate among COVID-19 patients.

  • Open Access

    Effect of edaravone on patients with moderate COVID-19: a single-center non-randomized clinical trial

    by Aysa Ghannadi, Seyyedeh Mina Hejazian, Mohammad Reza Moslemi, Farahnoosh Farnood, Bahram Niknafs, Sepideh Zununi Vahed, Khalil Ansarin, Mohammad Reza Ardalan, Parviz Saleh

    Background. The novel coronavirus disease 2019 (COVID-19) was declared a global pandemic. There is an urgent need for finding efficient medical treatments to diminish the high mortality rate of the mutant variants of the virus. This study aimed to determine the efficacy of edaravone in patients with moderate COVID-19. Methods. This single-center non-randomized controlled clinical trial was performed on hospitalized patients with moderate COVID-19. The patients were divided into two groups of intervention (n=17) and control (n=16). Patients in the intervention group received three doses of edaravone (30 mg) for three interval days (Days 2, 4, and 6). Admission to the intensive care unit (ICU), need for intubation, and mortality were the primary outcomes. Results. All cases had 15-60% lung involvement. Although edaravone reduced the admission to ICU, need for intubation, and mortality rate in patients with moderate COVID-19, the results were not statistically significant. Baseline characteristics, admission days, and clinical parameters were similar between the two groups (P>0.05). Conclusion. Administration of edaravone 30 mg for three days had no significant effect on the overall outcome of patients with moderate COVID-19. Practical Implications. In this study, none of the COVID-19 patients receiving edaravone had ICU admission, intubation, and mortality. However, no significant difference was found between the clinical outcomes of the control and intervention groups.

  • Open Access

    The early start of hemoperfusion decreases the mortality rate among severe COVID‐19 patients: A preliminary study

    by Haleh Mikaeili, Ali Taghizadieh, Masoud Nazemiyeh, Parisa Rezaeifar, Sepideh Zununi Vahed, Saeid Safiri, Mohammadreza Ardalan, Khalil Ansarin

    Background: Coronavirus disease‐2019 (COVID‐19)‐related organ failure is partly related to a sepsis‐like syndrome and extreme pro‐inflammatory cytokine release, named cytokine storm. Therapeutic strategies that prevent the production of or remove the pro‐inflammatory cytokines could potentially be an effective therapy in critically afflicted COVID‐19 patients.Methods: In this clinical trial study, from April until June 2020, 68 COVID‐19 patients (35 vs. 33 controls) with severe critical symptoms, and PaO2/FiO2 (P/F) ratio less than 200 mmHg either received a single standard therapy or a combination of standard treatment for COVID‐19 combined with hemoperfusion (hemofilter, HA330 D Javfron) for 4 h, in 3 consecutive days. The length of hospital stay and mechanical ventilation, the resolution of radiologic abnormalities, and the mortality rate were defined as the primary outcomes.Results: Demographic characteristics, the acute physiology, and chronic health evaluation score of both groups were similar (p > 0.05). Importantly, we noticed a significant mortality rate reduction in the perfused group compared with controls (37.1% vs. 63.6%, p = 0.02), this positive effect was stronger among those with a P/F ratio higher than 75 (mortality rate of 84.7% for P/F ratio < 75 vs. 15.4% for P/F ratio ≥ 75, p = 0.02).Conclusions: The results imply that early start of hemoperfusion could be more effective and significantly reduce the mortality rate among COVID‐19 patients with critical diseases.


  • Open Access

    Polymorphism (-499C/G) in DDAH2 promoter may act as a protective factor for metabolic syndrome: A case-control study in Azar-Cohort population

    by Elnaz Faramarzi, Younes Aftabi, Khalil Ansarin, Mohammad Hossein Somi, Neda Gilani, Ensiyeh Seyedrezazadeh

    Globally developing metabolic syndrome (MetS) prevalence as a major health problem can be related to multiple factors of genetic and environmental. Dimethylaminohydrolase 2 (DDAH2) is the main enzyme implicated in the cardiovascular system, which regulates the nitric oxide pathway. This study investigated the association of DDAH2 polymorphism -499C/G (rs805305) with the risk of MetS among the Azar-Cohort population. The occurrence of SNP rs805305 in the DDAH2 gene was tested using the PCR-RFLP method in 332 MetS cases and 294 healthy controls. Afterward, the association of the allele and genotypes with the risk of MetS and its components were examined. The G allele and GC genotype were significantly associated with a reduced risk of MetS (P ≤ 0.001). Also, the dominant genetic model (GG+GC) significantly decreased the risk of MetS (P = 0.001), however, in sex subtypes MetS risk was significantly reduced in males before and in females after adjustment for age (P ≤ 0.02). The -499C/G polymorphism of DDAH2 may play a protective role and reduce MetS risk among the Azar-Cohort population.